Company Overview and News
On paper, most analysts will agree that Activision Blizzard, Inc. (NASDAQ:ATVI) is enjoying a solid start to this year. Against the January opener, ATVI stock has gained nearly 9%. Given that the year is still relatively young, this consistently hot performer has enough time to make up some ground. Yet trouble is looming over the horizon for ATVI.
I don’t dislike Electronic Arts Inc. (NASDAQ:EA) stock. There’s an intriguing long-term case for the video game industry as a whole. EA stock has been an outstanding investment over time. And while Electronic Arts isn’t necessarily cheap, it still has the ability to grow into its valuation over time.
The reasons why could become more clear over the next couple of weeks. Activision Blizzard Inc., owner of popular franchises “Call of Duty” and “Overwatch,” reports first-quarter results on May 3. Electronic Arts Inc. reports the following week, while “Grand Theft Auto” publisher Take-Two Interactive Software Inc. will post later in the month. The results for the quarter ended March will be the first to reflect the impact—if any—of the surprise.
Take-Two Interactive Software, Inc (NASDAQ:TTWO) exemplifies the old Texas saying, “It’s not the size of the dog in the fight, but the size of the fight in the dog.”
Longer term, video game stocks have been on the rise, with Electronic Arts Inc. (NASDAQ:EA), Activision Blizzard, Inc. (NASDAQ:ATVI) and Take-Two Interactive Software, Inc (NASDAQ:TTWO) all hitting 52-weeks in 2018. However, shorter term, ATVI, TTWO and EA stock have been under pressure.
Truth be told, the recent selloff from Take-Two Interactive Software, Inc (NASDAQ:TTWO) makes reasonably good sense. Not only was TTWO stock pressured lower by the broad market’s weakness, the rise of Fortnite — a shooter game recently made available for mobile devices — seemingly posed a threat to the small(ish) video game publisher.
Mattel, Inc. (MAT - Free Report) , which remains focused on achieving cost savings, announced shutting down of its New York office. This latest move is a part of the company’s $650 million cost savings initiatives undertaken in 2017.
Sony Corp (ADR) (NYSE:SNE) has had a truly impressive run for a company its size. Since late 2012, Sony stock has quintupled, with SNE stock touching a nine-year high earlier this year before a modest pullback.
Coming off a strong 2017, games maker Glu Mobile Inc. (NASDAQ:GLUU) has been the center of a lot of buzz lately. However, that buzz hasn’t done much for GLUU stock.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET